5v24
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='5v24' size='340' side='right' caption='[[5v24]], [[Resolution|resolution]] 2.50Å' scene=''> | <StructureSection load='5v24' size='340' side='right' caption='[[5v24]], [[Resolution|resolution]] 2.50Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5v24]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V24 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V24 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5v24]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5V24 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5V24 FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=8V7:2-[4-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-3-YL]-N-(PYRIDIN-2-YL)-1,3-THIAZOLE-4-CARBOXAMIDE'>8V7</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=8V7:2-[4-(PROPAN-2-YL)-4H-1,2,4-TRIAZOL-3-YL]-N-(PYRIDIN-2-YL)-1,3-THIAZOLE-4-CARBOXAMIDE'>8V7</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5v19|5v19]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5v19|5v19]]</td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MAP3K5, ASK1, MAPKKK5, MEKK5 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase_kinase_kinase Mitogen-activated protein kinase kinase kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.25 2.7.11.25] </span></td></tr> | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase_kinase_kinase Mitogen-activated protein kinase kinase kinase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.11.25 2.7.11.25] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v24 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v24 OCA], [http://pdbe.org/5v24 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v24 RCSB], [http://www.ebi.ac.uk/pdbsum/5v24 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v24 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5v24 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5v24 OCA], [http://pdbe.org/5v24 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5v24 RCSB], [http://www.ebi.ac.uk/pdbsum/5v24 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5v24 ProSAT]</span></td></tr> | ||
| Line 24: | Line 25: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
[[Category: Mitogen-activated protein kinase kinase kinase]] | [[Category: Mitogen-activated protein kinase kinase kinase]] | ||
[[Category: Dougan, D R]] | [[Category: Dougan, D R]] | ||
Revision as of 10:28, 22 November 2017
Structure-based drug design of novel ASK1 inhibitors using a fully integrated lead optimization strategy
| |||||||||||
